Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2013 May;21(5):951-6.
doi: 10.1002/oby.20433.

Randomized double-blind placebo-controlled study of leptin administration after gastric bypass

Judith Korner  1 , Rushika Conroy, Gerardo Febres, Donald J McMahon, Irene Conwell, Wahida Karmally, Louis J Aronne
Affiliations
Randomized Controlled Trial

Randomized double-blind placebo-controlled study of leptin administration after gastric bypass

Judith Korner et al. Obesity (Silver Spring). 2013 May.

Abstract

Objective: Obese individuals have high levels of circulating leptin and are resistant to the weight-reducing effect of leptin administration at physiological doses. Although Roux-en-Y gastric bypass (RYGB) is an effective weight loss procedure, there is a plateau in weight loss and most individuals remain obese. This plateau may be partly due to the decline in leptin resulting in a state of relative leptin insufficiency. The main objective of this study was to determine whether leptin administration to post-RYGB patients would promote further weight reduction.

Design and methods: This was a randomized, double-blind, placebo-controlled cross-over study of 27 women who were at least 18 months post-RYGB and lost on average 30.8% of their presurgical body weight. Subjects received either leptin or placebo via subcutaneous injection twice daily for 16 weeks, then crossed over to receive the alternate treatment for 16 weeks.

Results: Weight change after 16 weeks of placebo was not significantly different from that after 16 weeks of leptin. No changes were observed in percent fat mass, resting energy expenditure, thyroid hormones, or cortisol levels.

Conclusion: Contrary to our hypothesis, we did not observe a significant effect of leptin treatment on body weight in women with relative hypoleptinemia after RYGB.

PubMed Disclaimer

Conflict of interest statement

CONFLICTS OF INTEREST

The rest of the authors have nothing to disclose.

Figures

Figure 1
Figure 1
Plasma leptin levels during the course of study. A) Group P-L, received placebo followed by leptin; and B) Group L-P, received leptin followed by placebo. Actual leptin values are indicated in the table as mean ± SEM. *P < 0.01; **P < 0.001 compared with Wk 0 within group.
Figure 2
Figure 2
Change in body weight during 16 weeks of either placebo or leptin administration.
See this image and copyright information in PMC

References

    1. Dardeno TA, Chou SH, Moon H-S, Chamberland JP, Fiorenza CG, Mantzoros CS. Leptin in Human Physiology and Therapeutics. Front Neuroendocrinol. 2010;31:377–393. - PMC - PubMed
    1. Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, et al. Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. Journal of the American Medical Association. 1999;282:1568–1575. - PubMed
    1. Paz-Filho G, Mastronardi C, Delibasi T, Wong M-L, Licinio J. Congenital Leptin Deficiency: Diagnosis and Effects of Leptin Replacement Therapy. Arq Bras Endocrinol Metab. 2010;24:690–7. - PMC - PubMed
    1. Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, et al. Effects of Recombinant Leptin Replacement Therapy in a Child with Leptin Deficiency. N Engl J Med. 1999;341:879–84. - PubMed
    1. Javor ED, Cochran EK, Musso C, Young JR, DePaoli AM, Gorden P. Long-Term Efficacy of Leptin Replacement in Patients with Generalized Lipodystrophy. Diabetes. 2005;54:1994–2002. - PubMed

Publication types